Back to mobile site

BofA/Merrill Lynch Downgrades Seattle Genetics (SGEN) to Underperform

February 10, 2017 8:44 AM EST Send to a Friend
BofA/Merrill Lynch downgraded Seattle Genetics (NASDAQ: SGEN) from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login